Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield - Iowa Kineret Coverage | O…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.10

    Kineret (anakinra) — Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.10 alerts

    Get alerted when Policy 05.02.10 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior-authorization, documentation, prescriber specialty, and medical necessity criteria for Kineret (anakinra) for FDA-approved and compendial indications for Blue Cross Blue Shield - Iowa members.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyKineret (anakinra) — Coverage Criteria
    Policy CodePolicy 05.02.10
    Change TypeNo material change
    Effective DateAug 14, 2026
    Last ReviewAug 14, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit prior authorization with required clinical documentation and evidence of prior therapy or contraindication as specified for the indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthstypical authorization duration
    3 monthsminimum methotrexate/biologic trial
    2preferred-product failures required
    28/28dRA quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    within 12 mo
    TB screening required

    Coverage Criteria for Kineret (anakinra)

    Moderately to severely active Rheumatoid Arthritis — Initial and general RA rules

    Covered when ALL of the following are met

    RA initial approval general: Authorization of 12 months may be granted for adult members for treatment of moderately to severely active rheumatoid arthritis when all of the following criteria are met
    Biomarker testing: Member meets either: (1) positive test for RF or anti-CCP OR (2) has been tested for RF, anti-CCP, and CRP and/or ESRpositive RF or anti-CCP; or testing for RF, anti-CCP, and CRP and/or ESR

    From Criteria A in policy

    Methotrexate trial: Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to at least 15 mg/week), or has intolerance or contraindication to methotrexate>= 3 months; methotrexate titrated to at least 15 mg/week

    Criteria B

    Prior biologic/tsDMARD trial: Member has experienced an inadequate response to at least a 3-month trial of a biologic or a targeted synthetic drug (e.g., Rinvoq, Xeljanz) or has intolerance to a biologic or targeted synthetic drug>= 3 months

    Criteria C

    RA preferred-product exception paths

    Initial approval for RA applies when at least ONE of the following is met

    Preferred-product failures or exceptions: A: Inadequate response to or intolerable adverse event with at least TWO preferred products (Enbrel, adalimumab-aacf, Rinvoq, Simponi, Xeljanz/Xeljanz XR)Failure of 2 preferred products

    Option A; submission of chart notes documenting outcomes, adverse events, contraindications, or exclusions is required where applicable.

    TNF avoidance alternative: B: Clinical reason to avoid TNF-inhibitors (Enbrel, adalimumab-aacf, Simponi) AND inadequate response to or intolerable adverse event with Rinvoq AND Xeljanz or Xeljanz XR

    See Appendix A for acceptable TNF-avoidance reasons

    Current effective therapy: C: Member is currently receiving the requested product through insurance (excludes samples or manufacturer's patient assistance programs) and is experiencing a positive therapeutic outcome

    Continued benefit must be documented

    Continuation Therapy

    Covered when ALL of the following are met for continuation:

    Multicentric Castleman's disease continuation: Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who have not experienced disease progression or unacceptable toxicity.12 months

    Continuation requirement for multicentric Castleman's disease

    CAR T-cell and immune checkpoint inhibitor-related toxicities: All members (including new members) requesting continuation of therapy for CAR T-cell–related or immune checkpoint inhibitor–related toxicities must meet all requirements in the coverage criteria.12 months

    Continuation requires meeting full coverage criteria

    Other indications continuation: Authorization of 12 months may be granted for members using the medication for an indication outlined in the Criteria for Initial Approval who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms.

    Safety and Dosing Requirements

    Coverage contingent on additional safety and dosing criteria:

    TB screening: Member has documented negative TB screening (TST or IGRA) within 12 months prior to initiating therapy if biologic- or targeted synthetic–naïve; if screening is positive, further testing to exclude active disease (e.g., chest x-ray) is required and latent TB must be treated before initiation; do not administer if active TB infection.TST/IGRA within 12 months

    Negative TB test required for biologic-naïve persons

    Concomitant biologic therapy: Member must not use the requested medication concomitantly with any other biologic drug or targeted synthetic drug.no concomitant biologic/targeted synthetic

    Per policy concomitant use is prohibited

    Dosing limits: Approvals are subject to dosing limits per FDA labeling, accepted compendia, or evidence-based guidelines. Quantity limits: RA — 28 syringes per 28 days; NOMID and DIRA — initial dosing 1 mg/kg, maintenance 3–4 mg/kg, maximum 8 mg/kg daily; all other indications — 112 syringes per 28 days.

    This medical policy may not apply to members covered under the Federal Employee Program (FEP). Benefit determinations for FEP members are governed by the Federal Employee Program and not by this Wellmark policy; verify benefits under the member's applicable FEP contract.

    Do not administer the requested medication to members with active tuberculosis (TB) infection. The policy requires documented TB screening (tuberculin skin test or interferon‑release assay) and, if screening is positive, further evaluation to exclude active disease (for example, chest x‑ray). If latent TB is identified, treatment must be started before initiating therapy.

    Kineret (anakinra) is considered not medically necessary for members who do not meet the coverage criteria set forth in this policy. Approvals are contingent on meeting the specified clinical criteria and any applicable dosing limits consistent with FDA labeling, accepted compendia, or evidence‑based guidelines.

    Procedures, Codes, and Quantity Limits

    Procedures and billing codesmixed
    No codes listed
    inv-09: TB screening timing
    Required testTuberculosis screening (TST or IGRA) must be documented within 12 months prior to initiating therapy for persons naïve to biologic or targeted synthetic drugs
    If screening positiveFurther testing (e.g., chest x‑ray) required to exclude active disease before initiating therapy
    Active TBDo not administer the medication to members with active tuberculosis infection
    Latent TBIf latent TB is identified, TB treatment must be started before initiation of therapy
    inv-10: Quantity limits (RA)
    RA quantity limit28 syringes per 28 days

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Prior authorization required — submit required clinical documentation

    Prior authorization is required for Kineret (anakinra). Submit the specified clinical documentation for the requested indication, including prior medication trials or clinical reasons to avoid preferred products where applicable. Authorization of up to 12 months may be granted when criteria are met.

    • Submit chart notes, medical records, or claims history documenting prior medications tried and responses (or clinical reason to avoid therapy).
    • Provide laboratory or biomarker results when required by indication (e.g., RF, anti-CCP, CRP/ESR for RA).
    Prior Authorization

    Authorization period and continuation — typically 12 months

    Authorizations for continuation or initial therapy may be granted for up to 12 months when the member meets the coverage criteria and has not experienced disease progression or unacceptable toxicity. Continuation requests must document ongoing positive clinical response as specified by indication.

    • Multicentric Castleman's disease: 12‑month reauthorization if no progression or unacceptable toxicity.

    Background on Anakinra (Kineret)

    Anakinra (Kineret) is an interleukin‑1 receptor antagonist indicated for multiple inflammatory conditions. The agent is listed in this policy for FDA‑approved uses such as moderately to severely active rheumatoid arthritis and for select autoinflammatory disorders; the policy also recognizes several compendial or off‑label inflammatory indications (for example, systemic juvenile idiopathic arthritis, adult‑onset Still's disease, recurrent pericarditis, and others). Use is managed through prior authorization, documentation of prior therapies or contraindications to preferred products, and adherence to safety requirements including TB screening and dosing/quantity limits.

    Definitions and Preferred Products

    inv-27: Preferred products list
    Preferred products listadalimumab-aacf; Enbrel (etanercept); Cosentyx; Otezla; Rinvoq (upadacitinib); Simponi; Skyrizi; Otulfi (ustekinumab-aauz); Tremfya; Xeljanz/Xeljanz XR
    Step-therapy requirementUse of two preferred products is required before non‑preferred products unless exceptions apply (clinical contraindication, current effective therapy, or only one preferred product exists)
    Program intentPolicy steers utilization to most cost‑effective medications within the therapeutic class
    inv-28: TB screening definition and timing
    DefinitionTB screening = tuberculosis skin test (TST) or interferon‑release assay (IGRA)
    Timing requirementTest must be performed within 12 months prior to initiating therapy for persons naïve to biologic or targeted synthetic drugs
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyKineret (anakinra) — Coverage Criteria
    Policy CodePolicy 05.02.10
    Change TypeNo material change
    Effective DateAug 14, 2026
    Last ReviewAug 14, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit prior authorization with required clinical documentation and evidence of prior therapy or contraindication as specified for the indication.
    SourceLink
    On This Page
    Coverage Criteria for Kineret (anakinra)Procedures, Codes, and Quantity LimitsProvider Actions, Documentation, and Prior AuthorizationBackground on Anakinra (Kineret)Definitions and Preferred Products
    12 months

    Applies to other labeled and compendial indications

    per labeling; RA 28 syringes/28 days; other indications 112 syringes/28 days

    Kineret considered not medically necessary when criteria are not met

    Related dosing noteQuantity limits apply in accordance with policy; RA-specific limit set at 28 syringes/28 days
    NOMID/DIRA distinctionPediatric NOMID and DIRA dosing described separately (weight‑based) and not subject to the standard RA syringe limit
    inv-11: Quantity limits (other indications)
    Non‑RA quantity limit112 syringes per 28 days for all other indications
    ExceptionsNOMID and DIRA have weight‑based initial and maintenance dosing (1 mg/kg initial; maintenance 3–4 mg/kg; max 8 mg/kg daily) rather than the standard syringe limits
    Apply per authorizationQuantity limits are applied per 28‑day authorization period consistent with FDA labeling and policy guidance
  1. CAR T– and immune checkpoint inhibitor–related toxicities: continuation only if all coverage requirements are met.
  2. All other indications: 12‑month authorization if positive clinical response or maintained low disease activity.
  3. Step Therapy

    Preferred-product step therapy — two preferred products required for RA

    For rheumatoid arthritis initial approvals, the program requires inadequate response or intolerable adverse events to at least TWO plan-preferred products (Enbrel, adalimumab-aacf, Rinvoq, Simponi, Xeljanz/Xeljanz XR) unless exception criteria apply.

    • Exceptions include clinical reasons to avoid TNF inhibitors (see policy Appendix A) with additional trial requirements, or current effective therapy with the requested product through insurance.
    • Preferred‑product requirement enforces use of two preferred agents before non‑preferred use unless excluded by documented clinical circumstances.
    Billing Rule

    No concomitant biologic/tsDMARD use; dosing and quantity limits

    The member may not receive Kineret concomitantly with any other biologic or targeted synthetic drug. Approvals may be subject to dosing limits consistent with FDA labeling, compendia, or evidence‑based guidelines.

    • Quantity limits: RA — 28 syringes per 28 days; all other indications — 112 syringes per 28 days.
    • NOMID and DIRA pediatric dosing: initial 1 mg/kg, maintenance 3–4 mg/kg, maximum 8 mg/kg daily; dosing must align with labeling.
    Documentation Required

    Rheumatoid arthritis — required documentation for initial and continuation requests

    For RA initial requests, provide chart notes, medical record documentation, or claims history documenting prior medications tried and responses (or reasons to avoid therapy) and laboratory/biomarker testing results (RF, anti‑CCP, and CRP and/or ESR) when applicable. For continuations, provide documentation of positive clinical response.

    • Document a ≥3‑month trial of methotrexate at adequate dosing (titrated to ≥15 mg/week) with inadequate response, or intolerance/contraindication to methotrexate.
    • Document prior inadequate response to a ≥3‑month trial of a biologic or targeted synthetic DMARD (e.g., Rinvoq, Xeljanz) or intolerance to such agents.
    Documentation Required

    AOSD and sJIA — documentation of prior therapy and response

    For AOSD and sJIA initial requests, submit chart notes, medical records, or claims history showing prior medications tried and responses; for continuation requests, submit documentation of positive clinical response.

    • If therapy is not advisable, provide documentation of clinical reason to avoid the prior therapy.
    Documentation Required

    NOMID — continuation documentation of positive response

    For NOMID continuation requests, provide chart notes, medical records, or laboratory results that support a positive clinical response to therapy.

    • Continuation approvals require evidence of maintained benefit (improvement in signs/symptoms or laboratory markers).
    Documentation Required

    DIRA — IL1RN mutation testing required for initial requests

    For DIRA initial requests, IL1RN mutation status must be provided as part of the prior authorization documentation.

    • Submit genetic testing results confirming IL1RN mutation status with the initial request.
    Documentation Required

    Recurrent pericarditis — prior therapy documentation required

    For recurrent pericarditis initial requests, submit chart notes, medical records, or claims history documenting prior medications tried and responses; for continuation, submit documentation of positive clinical response.

    • If prior therapies were not tried, document the clinical reason to avoid those therapies.
    Documentation Required

    HIDS/MKD — documentation of flares and global assessment/CRP

    For HIDS/MKD initial requests, provide chart notes, medical records, or laboratory results indicating the number of active flares within the last 6 months and a Physician's Global Assessment score or CRP level.

    • Continuation requests should include documentation of positive clinical response as applicable.
    Documentation Required

    Other compendial uses — prior therapy or reason to avoid required

    For compendial uses such as gout/pseudogout flares, CAR T‑related toxicities, and immune checkpoint inhibitor–related toxicity, initial requests must include chart notes, medical records, or claims history documenting prior medications tried and responses, or a clinical reason to avoid prior therapies.

    • Must meet both the Preferred Drug Plan Design and the Criteria for Initial Approval/Continuation when applicable.
    Documentation Required

    Required documentation — TB screening and evidence of response for reauthorization

    Documentation for all indications must include TB screening results (TST or IGRA within 12 months for persons naïve to biologic/targeted synthetic drugs) and evidence of clinical response or absence of disease progression for reauthorization; dosing must align with FDA labeling/compendia.

    • If TB screening is positive, further testing (e.g., chest x‑ray) must confirm no active disease; do not administer Kineret if active TB is present.
    • If latent TB is present, TB treatment must be started before initiating Kineret.
    Denial Risk

    Documentation required — missing documentation may cause denial

    Failure to submit required documentation — including chart notes, lab results, claims history, mutation testing when specified, or evidence of prior medication trials and responses — may result in denial of prior authorization.

    • Ensure inclusion of biomarker test results for RA and genetic confirmation for DIRA where applicable.
    • Include clear documentation of trials (duration and dose) for methotrexate and prior biologic/tsDMARDs when required.
    Denial Risk

    Denial triggers — active TB, unresolved positive TB screening, missing or nonconforming documentation

    Treatment requests may be denied if the member has active TB, if TB screening is positive without appropriate further evaluation or treatment for latent infection, if dosing exceeds approved limits, or if the member does not meet the policy criteria.

    • Do not administer Kineret to members with active TB infection.
    • Positive TB screening requires further evaluation (e.g., chest x‑ray) to exclude active disease; latent TB must be treated prior to initiation.
    Follow-up for positive testsPositive screening requires additional testing to exclude active disease before starting treatment; treat latent TB prior to therapy